Inactive Instrument

Onyx Pharmaceuticals, Inc.

Equities

US6833991093

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2013	Gilead Sciences, Inc. : Bradway's patient dealmaking brings Onyx to Amgen	RE
2013	Onyx Pharmaceuticals, Inc. : Onyx deal expected to give Amgen a big boost	RE

Onyx Pharmaceuticals, Inc. : Onyx Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference

January 02, 2013 at 09:09 pm

MarketScreener.com By

Onyx Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference

South San Francisco, CA. - Jan. 02, 2013

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 31st Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2013 at 9:30 a.m. Pacific Time.

To access the live webcast, log onto the company's website at:
http://www.onyx.com/investors/event-calendar

A replay will be available within 24 hours of the completion of the presentation through January 21, 2013.

About Onyx Pharmaceuticals, Inc.

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways.www.onyx.com.

distributed by

Latest news about Onyx Pharmaceuticals, Inc.

Gilead Sciences, Inc. : Bradway's patient dealmaking brings Onyx to Amgen	27/08/13	RE
Onyx Pharmaceuticals, Inc. : Onyx deal expected to give Amgen a big boost	26/08/13	RE
Onyx Pharmaceuticals, Inc. : Onyx deal expected to give Amgen a big boost	26/08/13	RE
AstraZeneca plc : AstraZeneca to buy U.S. cancer firm for up to $500 million	26/08/13	RE
Pfizer Limited : Amgen close to buying Onyx for $125 per share: sources	24/08/13	RE
Amgen, Inc. : Exclusive: Onyx provides drug trial data to potential bidders - sources	22/08/13	RE
Onyx Pharmaceuticals, Inc. : Amgen seeks drug trial data before finalizing Onyx deal: sources	15/08/13	RE
Bank of America Corp : Amgen deal for Onyx possible within week - sources	07/08/13	RE
Bank of America Corp : Amgen deal for Onyx possible within week-sources	07/08/13	RE
Biogen Idec Inc : Exclusive: Pfizer not moving forward with Onyx bid: sources	18/07/13	RE
Ranbaxy Laboratories Limited : Novartis lifts full-year outlook after competition delay	17/07/13	RE
Pfizer Inc. : Roche seeks financing for potential Alexion bid -sources	12/07/13	RE
Insmed Incorporated : S&P 500 extends gains to year's second half on solid data	01/07/13	RE
Onyx Pharmaceuticals, Inc. : Pfizer, Novartis may join Amgen in bidding for Onyx: sources	01/07/13	RE
Onyx Pharmaceuticals, Inc. : Onyx explores possible sale after rejecting Amgen offer	01/07/13	RE
Onyx Pharmaceuticals, Inc. : Onyx explores possible sale after rejecting Amgen offer	01/07/13	RE
L-3 Communications Holdings, Inc. : U.S. companies delay results due to Sandy	31/10/12	RE
L-3 Communications Holdings, Inc. : U.S. companies delay results due to Sandy	30/10/12	RE
BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion	16/07/12	RE
Ardea Biosciences, Inc. : Biotech targets fight back as Big Pharma circles	02/05/12	RE

Chart Onyx Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.13%	122B
REGENERON PHARMACEUTICALS, INC.	+19.65%	113B
ARGENX SE	+19.30%	26.49B
BIONTECH SE	-23.84%	19.4B
GENMAB A/S	-17.98%	16.24B
WUXI APPTEC CO., LTD.	-45.95%	15.15B
BEIGENE, LTD.	-19.28%	15.4B
SAREPTA THERAPEUTICS, INC.	+63.81%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+1.94%	13.52B

Bio Therapeutic Drugs